Summit Therapeutics

PriceSummit Therapeutics

SMMT

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Historical stock price chart and annual return over the past years

632%

5 years

% Total

SMMT
49%

5 years

Annual Return

SMMT